State University of New York - Upstate Medical University

upstate.edu

Total trials

155

Active

13

Phase 3

4

Total enrollment

11,854

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Sirolimus1
N-acetylcysteine1
Tafenoquine Oral1
Ceftriaxone1
Dextrose 5%1
Activated Charcoal2

Next readouts

  • 2026-05-01
  • 2026-12
  • 2027-03
  • 2027-03-31
  • 2029-01-01

Top conditions

  • Obesity4
  • Borderline Personality Disorder4
  • Schizophrenia4
  • Alcohol Dependence4
  • Autism Spectrum Disorder4
  • Osteoporosis3
  • Dengue3
  • Pain3

Frequently asked questions about State University of New York - Upstate Medical University

How many clinical trials does State University of New York - Upstate Medical University have on ClinicalTrials.gov?
State University of New York - Upstate Medical University is listed as the lead sponsor on 155 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of State University of New York - Upstate Medical University's trials are in Phase 3?
4 of State University of New York - Upstate Medical University's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does State University of New York - Upstate Medical University focus on?
State University of New York - Upstate Medical University's most-studied conditions on ClinicalTrials.gov are Obesity, Borderline Personality Disorder, Schizophrenia, Alcohol Dependence, Autism Spectrum Disorder.
When are State University of New York - Upstate Medical University's next clinical trial readouts?
State University of New York - Upstate Medical University has 5 upcoming primary-completion readouts tracked here; the soonest is “Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay”, expected around 2026-05-01.